1286278-36-1

Basic information

• Product Name: (S)-tert-butyl 4-(5-bromo-2-fluorophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate
• Synonyms: (S)-tert-butyl 4-(5-bromo-2-fluorophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate
• CAS NO: 1286278-36-1
• Molecular Weight: 414.274
• Mol File: 1286278-36-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-tert-butyl 4-(5-bromo-2-fluorophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 4-(5-bromo-2-fluorophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate(1286278-36-1)
• EPA Substance Registry System: (S)-tert-butyl 4-(5-bromo-2-fluorophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate(1286278-36-1)

Safety Data

• Hazardous Substances Data: 1286278-36-1(Hazardous Substances Data)

Upstream product

• 1254199-70-6 (S)-tert-butyl 4-(5-amino-2-fluorophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate 
• 1254199-54-6 (S)-tert-butyl 4-(2-fluoro-5-nitrophenyl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1H)-ylidenecarbamate 
• 1075230-62-4 (R)-2-methylpropane-2-sulfinic acid [1-(2-fluoro-5-nitrophenyl)-(E)-ethylidene]amide 
• 1213413-42-3 (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-butyric acid methyl ester 
• 1254199-42-2 methyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2-fluoro-5-nitrophenyl)butanoate 
• 4248-19-5 tert-butyl carbazate 
• 887913-52-2 (methylamino)thioxomethylcarbamic acid t-butyl ester 
• 445-27-2 2'-Fluoroacetophenone 
• 79110-05-7 1-(2-fluoro-5-nitrophenyl)ethanone 

Relevant articles and documents

PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (I): and tautomers thereof, and solvates, prodrugs, esters, and deuterates of said compounds and said tautomers, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R1, R2, R3, R4, R5, R9, R11, ring A, ring B, m, n, p, q, r, -L1-,L2-, and L3- is selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers Disease, are also disclosed.